Ascendis powers ahead on capital spending
Ascendis Pharma's year has been clinically heavy, which has affected the operating deficit, but 2021 will also have a heavy set of expenses while the company awaits the first product approval.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Ascendis Pharma left 2020 with a much larger operating cost deficit than for 2020.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis submits FDA application to start cancer trial
For subscribers
